Table 1.
SVR Rates in the HEPATHER Trial of Daclatasvir and Sofosbuvir in Patients With HCV Genotype 1
| Daclatasvir and Sofosbuvir (n=317) | Daclatasvir, Sofosbuvir, and Ribavirin (n=92) | |||
|---|---|---|---|---|
| 12 Weeks | 24 Weeks | 12 Weeks | 24 Weeks | |
| SVR4, n (%) | 46/54 (85.2) | 250/263 (95.1) | 12/12 (100) | 79/80 (98.7) |
| SVR12, n (%) | 45/53 (84.9) | 172/184 (93.4) | 11/11 (100) | 61/62 (98.4) |
| SVR4 in patients with cirrhosis, n (%) | 26/34 (76.5) | 203/216 (94.0) | 9/9 (100) | 59/60 (98.3) |
| SVR4 in patients without cirrhosis, n (%) | 20/20 (100) | 47/47 (100) | 3/3 (100) | 18/18 (100) |
| SVR4 in treatment-naive patients, n (%) | 27/31 (87.1) | 47/53 (88.7) | 4/4 (100) | 14/14 (100) |
| SVR4 in treatment-experienced patients, n (%) | 19/23 (82.6) | 203/210 (96.7) | 8/8 (100) | 65/66 (98.5) |
| SVR4 in patients who had received a prior protease inhibitor and peginterferon/ribavirin, n (%) | 4/5 (80.0) | 128/132 (97.0) | 4/4 (100) | 32/32 (100) |
| SVR4 in patients who had received prior peginterferon/ribavirin, n (%) | 15/18 (83.3) | 75/78 (96.1) | 4/4 (100) | 33/34 (97.1) |
HCV, hepatitis C virus; SVR4, sustained virologic response at week 4; SVR12, sustained virologic response at week 12.
Data from Pol S et al. Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the French observational cohort ANRS CO22 HEPATHER [EASL abstract LO3]. J Hepatol. 2015;62(1)(suppl).1